Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TaiDoc Technology Corporation (4736.TW)
New Taipei City, TW
TaiDoc Technology Corporation, established in 1998 and based in New Taipei City, Taiwan, is a leading global producer and distributor of a wide array of medical devices. The company's comprehensive product catalog features advanced in vitro diagnostics, including multi-parameter monitoring systems, convenient point-of-care testing (POCT) devices, and precision lancet and lancing tools. For animal health, TaiDoc offers specialized veterinary diagnostics such as blood glucose, calcium, and ketone meters. Beyond diagnostics, their general medical equipment range encompasses vital devices like nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. In the connected health sector, they develop remote telehealth monitoring devices alongside user-friendly smartphone applications. The company also contributes to infectious disease screening, providing rapid antigen test kits for conditions like COVID-19. In addition to its product offerings, TaiDoc delivers value-added services, assisting clients with regulatory professional guidance, clinical consultation, engineering support, and sophisticated manufacturing system solutions. Furthermore, they offer a suite of proprietary software applications designed to enhance device functionality and user experience, such as MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and a USB adapter driver.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.21% | -4.69% | -2.40% | -1.21% | -1.21% | +0.41% | -3.94% | -23.27% | -23.27% | -23.27% | -23.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-9.4% Q1'26: +10.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+24.1% Q1'26: +1,968.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+16.1% ★ Q1'26: +31.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+22.7% ★ Q1'26: +25.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+13.6% ★ Q1'26: +14.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+1.1% Q1'26: +3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.06× ★ Q1'26: 1.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
4.81B
est: 5.23B (-8.0%)
|
4.64B
est: 5.57B (-16.7%)
|
4.20B
est: 5.14B (-18.2%)
|
| EBITDA |
1.19B
est: 1.97B (-39.4%)
|
1.65B
est: 1.97B (-16.0%)
|
1.10B
est: 1.81B (-39.7%)
|
| EBIT |
1.34B
est: 1.78B (-24.6%)
|
1.48B
est: 1.77B (-16.3%)
|
956.21M
est: 1.63B (-41.5%)
|
| Net Income |
1.02B
est: 1.12B (-9.0%)
|
1.16B
est: 1.07B (+8.0%)
|
1.44B
est: 929.00M (+55.2%)
|
| SGA |
785.77M
est: 750.57M (+4.7%)
|
867.39M
est: 834.23M (+4.0%)
|
713.51M
est: 769.53M (-7.3%)
|
| EPS |
10.67
est: 11.68 (-8.6%)
|
12.10
est: 11.09 (+9.1%)
|
15.12
est: 9.60 (+57.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 23.7K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 50.7K | 0.65% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 19.8K | 0.56% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 31.7K | 0.44% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 714.6K | 0.06% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 75.2K | 0.46% |
| 7 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 7.9K | 0.33% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 305.0K | 0.39% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 24.3K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 54.9K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaowang Chen | Chairman of the Board, GM & President | — | male |
| Dong-Quan Zhan | Vice President of R&D Division Representative Director | — | male |
| Hong-Zhi Ji | Executive Vice President of Sales Division & Director | — | male |
| Jia-Qi Wu | Deputy General Manager | — | female |
| Qiting Huang | Associate Manager of Financial & Accounting, Chief Accountant and Accounting Supervisor | — | female |
| Tai-Cheng Zhou | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4736.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
